Cantor Fitzgerald set a $65.00 price target on AVITA Med Ltd/S (OTCMKTS:AVMXY) in a research report released on Thursday morning. The firm currently has a buy rating on the medical device company’s stock.

OTCMKTS:AVMXY opened at $1.75 on Thursday. AVITA Med Ltd/S has a twelve month low of $0.75 and a twelve month high of $2.15.

About AVITA Med Ltd/S

Avita Medical Limited, a medical device company, develops and distributes regenerative products for the treatment of a range of wounds, scars, and skin defects in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. Its patented and proprietary collection and application technology provides treatment solutions derived from a patient's own skin.

Featured Story: Return on Investment (ROI)

Receive News & Ratings for AVITA Med Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVITA Med Ltd/S and related companies with's FREE daily email newsletter.